Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 3Pancreatic Neoplasms 3Cholangiocarcinoma 3Squamous Cell Carcinoma of Head and Neck 2Recurrence 2Neoplasm Metastasis 2Carcinoma, Non-Small-Cell Lung 2Vulvar Neoplasms 1Vaginal Neoplasms 1Urothelial Bladder Carcinoma 1Urinary Bladder Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thymoma 1Stomach Neoplasms 1Sarcoma 1Rectal Neoplasms 1Pharyngeal Neoplasms 1Oropharyngeal Neoplasms 1Oligometastatic Prostate Cancer 1Mouth Neoplasms 1Melanoma 1Lung Diseases 1Locally Advanced Pancreatic Cancer 1Locally Advanced Cervical Cancer 1Liver Neoplasms 1Liposarcoma 1Laryngeal Neoplasms 1Kidney Neoplasms 1Hypopharyngeal Neoplasms 1

Interventions

Gemcitabine 24Cisplatin 14Capecitabine 12Oxaliplatin 11Fluorouracil 11Leucovorin 7Irinotecan 7Radiotherapy 5durvalumab 4Photochemotherapy 3Magnetic Resonance Spectroscopy 3Long-Term Synaptic Depression 3Erlotinib Hydrochloride 3Cholangiopancreatography, Endoscopic Retrograde 3Carboplatin 3trifluridine tipiracil drug combination 2regorafenib 2olaparib 2ceralasertib 2Stents 2Sorafenib 2Radiosurgery 2Radiofrequency Ablation 2Liver Transplantation 2Filgrastim 2Dihematoporphyrin Ether 21-phenyl-3,3-dimethyltriazene 2zimberelimab 1tivozanib 1titanium silicide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Bile Duct Neoplasms × zimberelimab × Clear all
NCT06048133 2026-01-23

Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)

Big Ten Cancer Research Consortium

Phase 2 Recruiting
33 enrolled
Gastrointestinal

Bile Duct Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡